Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Document › Details

4SC AG. (8/18/14). "Press Release: Dr Thomas Werner und Klaus Kühn Announce Resignation for Supervisory Board".

Organisation Organisation 4SC AG (FSE: VSC)
  Group 4SC (Group)
Product Product small-molecule cancer drug
Persons Person Werner, Thomas (Board Member of several companies before GSK SVP)
  Person 2 Kühn, Klaus (Bayer 200603 CFO)

4SC AG (Frankfurt, Prime Standard: VSC) announces that Dr Thomas Werner and Klaus Kühn have informed the company today that they will resign from their positions as members of the Supervisory Board of 4SC AG for personal reasons effective at the end of 18 September 2014. Dr Werner has been a member of 4SC's Supervisory Board since June 2009, serving as its Chairman since June 2012; Mr Kühn has been a member of the Supervisory Board since August 2012.

The remaining Supervisory Board consisting of four members remains fully quorate. 4SC will provide timely information about how the vacant positions will be filled.

The Management Board of 4SC AG thanks Dr Werner and Mr Kühn for their commendable service and their strong dedication to the company.

Information and Explaination of the Issuer to this News:

Enno Spillner, Chief Executive Officer of 4SC AG, comments: 'On behalf of the 4SC Management Board, I wish to thank Dr Werner and Mr Kühn for their great dedication to 4SC and for their collaboration in the past years, which was always fair, positive and constructive. We regret their departure very much. We will now work with our full dedication to promptly find competent and experienced successor candidates from our industry-wide network, whom we will nominate for replacement in accordance with the regulatory framework.'

About 4SC

The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops targeted, small-molecule drugs for treating diseases with high unmet medical needs in various cancer and autoimmune indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company's pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies. Founded in 1997, 4SC had a headcount of 65 employees (55 FTEs) at 30 June 2014. 4SC AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.

Cautionary statement regarding forward-looking statements

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and 4SC AG has no obligation to update any such information or to correct any inaccuracies herein or omission herefrom which may become apparent.

For more information please visit or contact:

Jochen Orlowski, Corporate Communications & Investor Relations
jochen.orlowski(at), Tel.: +49-89-7007-6366

MC Services
Katja Arnold, Michelle Kremer
katja.arnold(at), Tel.: +49-89-2102-2840

The Trout Group
Chad Rubin
crubin(at), Tel.: +1-646-378-2947

Record changed: 2017-04-02


Picture [iito] Plain Stupid Simple 650x80px

More documents for 4SC (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] No Content Marketing 650x80px

» top